Opus Genetics Inc., has announced new data on the potential of gene therapy treatments from RDH12- and MERTK-associated retinal degenerations.
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new data on preparing AAV-based gene therapy programs to… Read More »Opus Genetics Inc., has announced new data on the potential of gene therapy treatments from RDH12- and MERTK-associated retinal degenerations.